Cisplatin (CDDP): Benchmark DNA Crosslinking Agent for Cancer Research

Executive Summary: Cisplatin (CAS 15663-27-1), also known as CDDP, is a platinum-based chemotherapeutic compound with a molecular weight of 300.05 and formula Cl₂H₆N₂Pt. It functions by crosslinking DNA at guanine bases, triggering DNA damage response and apoptosis via p53 and caspase signaling (Am J Cancer Res 2020;10(8):2621-2634, APExBIO). Cisplatin induces oxidative stress, elevates ROS, and activates ERK-dependent apoptosis. It is widely used in apoptosis assays, xenograft models, and in studies of chemotherapy resistance. The compound is insoluble in water and ethanol, soluble in DMF at ≥12.5 mg/mL, and requires dark, room-temperature storage for stability (APExBIO).

Biological Rationale

Cisplatin is a first-line DNA crosslinking agent for cancer research, selected for its unique ability to induce inter- and intra-strand DNA crosslinks at guanine residues. These lesions inhibit both DNA replication and transcription, leading to activation of the DNA damage response and programmed cell death (apoptosis) in rapidly dividing cells (Cisplatin: Benchmark DNA Crosslinking Agent for Cancer Research). This distinguishes cisplatin from alkylating agents and antimetabolites, which have different spectra of DNA interaction and cell cycle effects. In the context of triple-negative breast cancer and other aggressive tumors, cisplatin's ability to bypass some resistance mechanisms has made it a keystone in both research and clinical protocols (Am J Cancer Res 2020;10(8):2621-2634).

Mechanism of Action of Cisplatin

Cisplatin enters the cell via passive diffusion and copper transporter proteins. Inside the cell, chloride ligands are replaced by water, leading to a reactive platinum species that forms covalent bonds with the N7 position of guanine bases in DNA. This results in both intra- and inter-strand crosslinks which block DNA polymerase, stalling replication forks and transcription complexes. The DNA damage activates ATM/ATR kinases and leads to p53 stabilization. Downstream, this triggers caspase-9 and caspase-3 activation, culminating in apoptosis (Cisplatin in Cancer Research: Unraveling Resistance and Apoptosis). In parallel, cisplatin increases intracellular ROS, further damaging DNA, proteins, and lipids, and promoting apoptosis via ERK-dependent signaling pathways. These effects are dose-dependent and cell-type specific.

Evidence & Benchmarks

• Cisplatin forms DNA crosslinks at the N7 position of guanine, blocking DNA replication and transcription (APExBIO Product Data).
• Triggers p53 stabilization and subsequent caspase-9 and caspase-3 activation, leading to apoptosis (Am J Cancer Res 2020;10(8):2621-2634, PDF).
• Induces oxidative stress and ROS accumulation, enhancing ERK-dependent apoptotic pathways (Cisplatin in Cancer Research: Cellular Signaling, Resistance).
• In vivo, intravenous dosing of 5 mg/kg on days 0 and 7 significantly inhibits tumor growth in xenograft models (APExBIO).
• Solubility profile: insoluble in water and ethanol, but soluble in DMF at ≥12.5 mg/mL; DMSO inactivates cisplatin (APExBIO).
• Cisplatin resistance is associated with upregulation of DNA repair pathways and ER stress proteins such as GRP78 (Am J Cancer Res 2020;10(8):2621-2634).

Applications, Limits & Misconceptions

Cisplatin is extensively used in cancer research for:

• Apoptosis assays measuring caspase activation and DNA fragmentation.
• Tumor growth inhibition studies in xenograft models.
• Investigation of chemotherapy resistance mechanisms.
• Dissection of p53-mediated signaling and ERK-dependent apoptotic pathways.

This article extends previous overviews by providing atomic, verifiable benchmarks and clarifies how cisplatin’s effects are context-dependent, especially in models of triple-negative breast cancer. For a detailed mechanistic comparison, see Cisplatin in Translational Oncology: Mechanistic Insights, which discusses platinum resistance and the role of CLK2, whereas this article emphasizes DNA crosslinking and apoptosis benchmarks.

Common Pitfalls or Misconceptions

• Cisplatin is not soluble in water or ethanol; improper solvents can inactivate the compound (APExBIO).
• DMSO must be avoided as it deactivates cisplatin’s activity (APExBIO).
• Stability is limited in solution; aliquots must be freshly prepared and protected from light (APExBIO).
• Not all cell lines respond equally; resistance can develop via DNA repair or ER stress pathways (Am J Cancer Res 2020;10(8):2621-2634).
• Apoptosis induction is dose-, time-, and cell-type dependent; results should be normalized to these variables.

Workflow Integration & Parameters

Cisplatin (A8321) from APExBIO is provided as a powder, ensuring stability under dark, room-temperature conditions. For solution preparation, dissolve in DMF at ≥12.5 mg/mL, utilizing gentle warming and ultrasonic treatment to enhance solubility. Solutions should be freshly prepared; avoid DMSO. Typical in vivo dosing in xenograft models is 5 mg/kg IV on days 0 and 7. For apoptosis assays, dose and exposure time must be titrated for each cell line. Integration into workflows investigating DNA damage, apoptosis, and chemotherapy resistance is supported by robust historical benchmarks. For troubleshooting and advanced applications, Cisplatin: Benchmark DNA Crosslinking Agent for Cancer Research provides workflow optimizations, while this article supplies updated, atomic claims and links to mechanistic insights.

Conclusion & Outlook

Cisplatin (CDDP) remains the definitive DNA crosslinking agent and apoptosis inducer for cancer research, with a well-characterized mechanism involving DNA adduct formation, p53 activation, caspase signaling, and ROS induction. Its utility extends across apoptosis assays, tumor inhibition studies, and resistance modeling. Ongoing research is clarifying new resistance mechanisms, such as the role of ER stress proteins like GRP78, underscoring the need for precise application and interpretation of results (Am J Cancer Res 2020;10(8):2621-2634). For researchers requiring reliable, well-characterized reagents, APExBIO’s Cisplatin (A8321) provides validated performance and robust technical support (product details).